Korro Bio, Inc. expected to post a loss of $1.43 a share - Earnings Preview

Korro Bio

07/08/2026 17:24

Korro Bio, Inc. KRRO.OQ KRRO.O is expected to  show a fall in quarterly revenue when it reports  results  for the period ending September 30 2026
The Cambridge Massachusetts-based  company is expected to report a 80.3% decrease in revenue to $214.29 thousand from $1.09 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Korro Bio, Inc. is for a loss of $1.43 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts had fallen by about 11.9% in the last three months. ​
Wall Street's median 12-month price target for Korro Bio, Inc. is $22.00, about 81.5% above its last closing price of $12.12
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-1.43
-1.45
-1.07
Beat
26.2
Mar. 31 2026
-1.73
-1.84
-1.69
Beat
8.3
Dec. 31 2025
-1.95
-2.07
-1.65
Beat
20.2​
Sep. 30 2025
-2.47
-2.59
-1.92
Beat
26
​​Jun. 30 2025
-2.39
-2.56
-2.74
Missed
-6.8
Mar. 31 2025
-2.55
-2.60
-2.49
Beat
4.4​
Dec. 31 2024
-2.00
-2.48
-2.26
Beat
8.9
Sep. 30 2024
-2.60
-2.61
-2.26
Beat
13.4
This summary was machine generated August 7 at 16:24 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)